CA2322750A1 - Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes - Google Patents

Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes Download PDF

Info

Publication number
CA2322750A1
CA2322750A1 CA002322750A CA2322750A CA2322750A1 CA 2322750 A1 CA2322750 A1 CA 2322750A1 CA 002322750 A CA002322750 A CA 002322750A CA 2322750 A CA2322750 A CA 2322750A CA 2322750 A1 CA2322750 A1 CA 2322750A1
Authority
CA
Canada
Prior art keywords
antigen
cell
leu
cells
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002322750A
Other languages
English (en)
Inventor
Charles A. Nicolette
Johanne Kaplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2322750A1 publication Critical patent/CA2322750A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions et des méthodes d'immunothérapie, destinées en particulier à induire une réponse immunitaire contre un antigène, chez un patient. Dans un aspect, cette invention concerne des cellules génétiquement modifiées présentatrices de l'antigène, qui constituent des présentatrices plus puissantes d'un peptide exogène que les cellules mères présentatrices de l'antigène. L'invention concerne également des compositions renfermant ces cellules génétiquement modifiées, ainsi qu'un excipient, par exemple un excipient pharmaceutiquement acceptable. Ces cellules génétiquement modifiées présentatrices de l'antigène peuvent notamment être utilisées en immunothérapie adoptive, ou pour accroître une population sensiblement pure de cellules immunitaires effectrices. L'invention concerne enfin des méthodes permettant accroître une population sensiblement pure de cellules.
CA002322750A 1998-03-20 1999-03-19 Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes Abandoned CA2322750A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7888098P 1998-03-20 1998-03-20
US60/078,880 1998-03-20
PCT/US1999/006031 WO1999047102A2 (fr) 1998-03-20 1999-03-19 Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes

Publications (1)

Publication Number Publication Date
CA2322750A1 true CA2322750A1 (fr) 1999-09-23

Family

ID=22146768

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322750A Abandoned CA2322750A1 (fr) 1998-03-20 1999-03-19 Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes

Country Status (5)

Country Link
EP (1) EP1063891A4 (fr)
JP (1) JP2002506622A (fr)
AU (1) AU755156B2 (fr)
CA (1) CA2322750A1 (fr)
WO (1) WO1999047102A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1730263A4 (fr) * 2004-03-02 2008-01-23 Tsuneya Ohno Procedes et compositions ayant trait a des vaccins de cellules hybrides de traitement et prevention du cancer
EP1794327B1 (fr) 2004-09-14 2016-11-30 Argos Therapeutics, Inc. Amplification de souches independantes d'agents pathogenes et vaccins les comprenant
WO2009008713A1 (fr) * 2007-07-09 2009-01-15 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce Inhibiteurs de tap à partir d'herpèsvirus 1 de primate d'europe et leur utilisation
CN104761644A (zh) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用
US20170363629A1 (en) * 2014-11-05 2017-12-21 Board Of Regents, The University Of Texas System Biomarkers and targets for cancer immunotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5750398A (en) * 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
WO1997007128A1 (fr) * 1995-08-21 1997-02-27 Duke University Procede pour accroitre la densite d'un antigene sur une cellule presentant un antigene

Also Published As

Publication number Publication date
WO1999047102A3 (fr) 1999-10-21
AU755156B2 (en) 2002-12-05
EP1063891A4 (fr) 2002-10-23
EP1063891A2 (fr) 2001-01-03
AU3102399A (en) 1999-10-11
WO1999047102A2 (fr) 1999-09-23
JP2002506622A (ja) 2002-03-05

Similar Documents

Publication Publication Date Title
US6440735B1 (en) Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer
US20020164346A1 (en) Altered peptide ligands
CA2547635A1 (fr) Epitope de lymphocyte t cytotoxique humain et son epitope agoniste issus du nombre non variable de sequences repetees en tandem de muc-1
US7824849B2 (en) Cellular telomerase vaccine and its use for treating cancer
AU755156B2 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
AU758265B2 (en) Induction of immunity against tumor self-antigens
EP1064354A1 (fr) Compositions et methodes pour provoquer une reponse des cellules t par des vaccins a base de genes
AU759765B2 (en) Compositions and methods for antigen-specific vaccination
US20020065241A1 (en) Antigenic peptide concatomers
AU1102100A (en) Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation
JP2004525072A (ja) 抗黒色腫治療化合物
EP1309625B1 (fr) Composes therapeutiques contre le cancer des ovaires
AU2014268156A1 (en) A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
AU2002250114A1 (en) Altered peptide ligands

Legal Events

Date Code Title Description
FZDE Discontinued